Torii Pharmaceutical

Trending

View All

Pharma News for Eisai, Biogen, Merck, BMS, Kyverna

Dec 19, 2023

Eisai Submits Marketing Authorization Application for Tasurgratinib; CHMP Issues Positive Opinion for Biogen’s SKYCLARYS; European Commission Approves Merck’s KEYTRUDA + Chemotherapy HER2-ve Gastric or GEJ Adenocarcinoma; BMS Provides Update on RELATIVITY-123 Trial; Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101; Verrica and Torii Pharma Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208

Eisai Submits Marketing Authorization Application In Japan for Anticancer Agent Tasurgratinib For Biliary Tract Cancer With FGFR2 Gene Fusion Eisai Co., Ltd. has officially submitted a request for marketing authorization in Japan for tasurgratinib succinate, its internally developed tyrosine kinase inhibitor tar...

Find More

Editor's Pick

Wainua – The Only Approved Medicine for hATTR-PN Treatment

lyfgenia-or-casgevy-for-sickle-cell-disease-treatment

Lyfgenia or Casgevy: Who Will Lead the Sickle Cell Disease Treatment Space?

Another Feather in the Cap for Xtandi and Keytruda — The Two Main Cancer Drugs

vabysmo-for-retinal-vein-occlusion-treatment

Roche’s Vabysmo Third US Approval Spiced Up the Battle With Regeneron and Bayer’s Eylea

AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure

Newsletter/Whitepaper

ASCO Conference 2023

The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.

Catch the Glimpse here

By DelveInsight

Torii Pharmaceutical

Search by Categories

Our expertise in the industry

View All

Editor's Pick

Newsletter/Whitepaper

ASCO Conference 2023